marimastat has been researched along with Breast Cancer in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X; He, W; Lin, C; Lv, Y; Qin, C; Xin, X; Xu, C; Yang, L; Yang, X; Yin, L; Zhang, L; Zhao, X | 1 |
| He, W; Xiao, Q; Yin, L; Yuan, Y; Zhu, X | 1 |
| Haage, A; Schneider, IC | 1 |
| Adam, MJ; auf dem Keller, U; Bellac, CL; Bénard, F; Dedhar, S; Harwig, C; Kappelhoff, R; Lange, PF; Li, Y; Lou, Y; Overall, CM; Perrin, DM; Ruth, TJ; Ting, R | 1 |
| Cobleigh, M; Gradishar, W; Miller, KD; Rasmussen, H; Robert, N; Schuchter, L; Sledge, GW; Sparano, JA | 1 |
| Moses, MA; Pories, SE; Roy, R; Wewer, UM; Zurakowski, D | 1 |
| Bernardo, P; Davidson, NE; Gradishar, WJ; Ingle, JN; Sparano, JA; Stephenson, P; Zucker, S | 1 |
| Davidson, NE; Gradishar, WJ; Ingle, JN; Sparano, JA; Wang, M; Zucker, S | 1 |
| McCann, PP; Rasmussen, HS | 1 |
| Brown, PD | 1 |
| Fletcher, L | 1 |
| Balduyck, M; Dacquembronne, E; Dejonghe, MJ; Duhem, T; Gouyer, V; Grard, G; Hemon, B; Huet, G; Lebrun, A; Lemaire, R; Lemaire, V; Thiebaut, C; Zerimech, F | 1 |
1 review(s) available for marimastat and Breast Cancer
| Article | Year |
|---|---|
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Enzyme Inhibitors; Female; Hemangioma; Humans; Hydroxamic Acids; Melanoma; Metalloendopeptidases; Mice; Ovarian Neoplasms; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Skin Neoplasms; Thiophenes | 1997 |
3 trial(s) available for marimastat and Breast Cancer
| Article | Year |
|---|---|
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Safety; Survival Rate; Treatment Outcome | 2002 |
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxamic Acids; Matrix Metalloproteinase 7; Matrix Metalloproteinase 9; Middle Aged; Placebos; Predictive Value of Tests; Prognosis | 2006 |
8 other study(ies) available for marimastat and Breast Cancer
| Article | Year |
|---|---|
Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Enzyme Inhibitors; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Liposomes; MCF-7 Cells; Mice, Inbred BALB C; Paclitaxel; Prodrugs; Tumor Microenvironment | 2018 |
A drug-delivering-drug strategy for combined treatment of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caseins; Cell Proliferation; Drug Combinations; Drug Delivery Systems; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinases; Mice; Nanoparticles; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Shape; Collagen; Elasticity; Extracellular Matrix; Gels; Heparan Sulfate Proteoglycans; Heparin Lyase; Humans; Hydroxamic Acids; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; Recombinant Proteins | 2014 |
Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer.
Topics: Animals; Borates; Breast Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Female; Fluorine Radioisotopes; Humans; Hydroxamic Acids; Isoenzymes; Isotope Labeling; Mammary Neoplasms, Experimental; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage.
Topics: ADAM Proteins; ADAM12 Protein; Adult; Aged; Amino Acid Sequence; Animals; Blotting, Western; Breast Neoplasms; Caseins; Catalysis; Chelating Agents; Chromatography, Affinity; Chromatography, Ion Exchange; Collagen Type I; Collagen Type IV; COS Cells; Databases as Topic; Densitometry; Disease Progression; Edetic Acid; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Extracellular Matrix; Female; Fibronectins; Gelatin; Humans; Hydroxamic Acids; Immunoblotting; Membrane Proteins; Metalloendopeptidases; Middle Aged; Molecular Sequence Data; Neoplasm Metastasis; Peptides; Phenanthrolines; Plasmids; Recombinant Proteins; Sensitivity and Specificity; Sepharose; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substrate Specificity; Ultracentrifugation; Zinc | 2004 |
Ongoing trials with matrix metalloproteinase inhibitors.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Organic Chemicals; Phenylbutyrates | 2000 |
MMPI demise spotlights target choice.
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Industry; Female; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors | 2000 |
Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro.
Topics: Base Sequence; Basement Membrane; Breast Neoplasms; Collagen; DNA Primers; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Hydroxamic Acids; Laminin; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2000 |